L01XY - otsingu tulemused

Euroopa Liit - eesti - EMA (European Medicines Agency)

phesgo

roche registration gmbh - pertuzumab, trastuzumab - rinnanäärmed - antineoplastilised ained - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Euroopa Liit - eesti - EMA (European Medicines Agency)

vyxeos liposomal (previously known as vyxeos)

jazz pharmaceuticals ireland limited - daunorubicin hydrochloride, cytarabine - leukeemia, müeloidne, äge - antineoplastilised ained - vyxeos liposomal on näidustatud ravi täiskasvanud, kellel on äsja diagnoositud, ravi seotud ägeda müeloidse leukeemia (t-aml) või aml koos myelodysplasia seotud muutused (aml-mrc).

Euroopa Liit - eesti - EMA (European Medicines Agency)

opdualag

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoom - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Eesti - eesti - Ravimiamet

doxy-m-ratiopharm 100 mg tablett

ratiopharm gmbh - doksütsükliin - tablett - 100mg 10tk; 100mg 20tk

Eesti - eesti - Ravimiamet

doxy-200 ws suukaudse lahuse pulber

interchemie werken de adelaar eesti aktsiaselts - doksütsükliin - suukaudse lahuse pulber - 173,3mg 1g 1000g 1tk

Eesti - eesti - Ravimiamet